X0306 4 2020-02-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001755198 Boissel Stephane C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94005 0 1 0 0 EVP, Corp. Strategy Common Stock 2020-02-25 4 F 0 2384 6.80 D 15116 D Common Stock 2020-02-25 4 A 0 55000 0.00 A 70116 D Stock Option (Right-to-Buy) 6.80 2020-02-25 4 A 0 110000 0.00 A 2030-02-24 Common Stock 110000 110000 D Represents shares underlying the portion of the restricted stock unit grant that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan. Includes 3,449 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and 11,667 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Represents 55,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such vesting date. /s/ Matthew Colvin, Attorney-in-Fact for Stephane Boissel 2020-02-26